Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,434,756
  • Shares Outstanding, K 121,640
  • Annual Sales, $ 335,660 K
  • Annual Income, $ 71,140 K
  • 60-Month Beta 1.88
  • Price/Sales 18.84
  • Price/Cash Flow 82.02
  • Price/Book 6.18
Trade DNLI with:

Options Overview Details

View History
  • Implied Volatility 70.40%
  • Historical Volatility 46.83%
  • IV Percentile 54%
  • IV Rank 43.99%
  • IV High 86.23% on 10/29/20
  • IV Low 57.96% on 06/15/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 176
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 14
  • Open Int (30-Day) 257

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.49
  • Number of Estimates 7
  • High Estimate -0.10
  • Low Estimate -0.66
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +9.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.02 +4.04%
on 09/20/21
56.80 -10.21%
on 09/02/21
-1.38 (-2.63%)
since 08/24/21
3-Month
47.02 +8.46%
on 07/26/21
79.70 -36.01%
on 06/30/21
-22.44 (-30.56%)
since 06/24/21
52-Week
34.34 +48.51%
on 09/25/20
93.94 -45.71%
on 12/22/20
+16.21 (+46.59%)
since 09/24/20

Most Recent Stories

More News
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

DNLI : 51.00 (-3.59%)
Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.

BIIB : 291.71 (-0.51%)
SGMO : 9.60 (-2.34%)
SAGE : 45.42 (-1.69%)
DNLI : 51.00 (-3.59%)
Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

DNLI : 51.00 (-3.59%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.14% and -28.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 51.00 (-3.59%)
Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

DNLI : 51.00 (-3.59%)
Will Denali Therapeutics Inc. (DNLI) Report Negative Q2 Earnings? What You Should Know

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DNLI : 51.00 (-3.59%)
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)

-- Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in...

DNLI : 51.00 (-3.59%)
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

DNLI : 51.00 (-3.59%)
New Strong Sell Stocks for July 7th

ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.

FHB : 28.64 (+0.53%)
DNLI : 51.00 (-3.59%)
GH : 128.40 (-0.71%)
FSLY : 42.04 (-2.41%)
ACCD : 43.06 (-2.86%)
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases,...

DNLI : 51.00 (-3.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO,...

See More

Key Turning Points

3rd Resistance Point 54.51
2nd Resistance Point 53.68
1st Resistance Point 52.34
Last Price 51.00
1st Support Level 50.18
2nd Support Level 49.35
3rd Support Level 48.01

See More

52-Week High 93.94
Fibonacci 61.8% 71.17
Fibonacci 50% 64.14
Fibonacci 38.2% 57.11
Last Price 51.00
52-Week Low 34.34

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar